2024-01-08 11:59:25 ET
Vincerx Pharma ( NASDAQ: VINC ) shares jumped above 45% on Monday after the biopharmaceutical company reported positive efficacy data for a relapsed/refractory lymphoma combination therapy.
Investigators from the National Institutes of Health observed two partial responses in three peripheral T-cell lymphoma patients and 1 partial response in two double-hit diffuse large b-cell lymphoma (DH-DLBCL) patients in ongoing dose-escalation Phase 1 trial of enitociclib in combination with venetoclax and prednisone.
Vincerx's ( VINC ) pipeline consists of the next-generation antibody-drug conjugate, VIP943, which is in Phase 1; small molecule-drug conjugate, VIP236, in Phase 1; preclinical antibody-drug conjugate, VIP924; CDK9 inhibitor, enitociclib, in the NIH-sponsored Phase 1; and VersAptx, its next-generation bioconjugation platform.
The firm remains on target to report early clinical data from its lead VersAptx platform compounds, VIP236 in early 2024 and VIP943 in mid 2024.
More on Vincerx Pharma
- Seeking Alpha’s Quant Rating on Vincerx Pharma
- Historical earnings data for Vincerx Pharma
- Financial information for Vincerx Pharma
For further details see:
Vincerx Pharma stock rises on positive efficacy data from lymphoma therapy